Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions |
umls-concept:C0010453,
umls-concept:C0017526,
umls-concept:C0021755,
umls-concept:C0021760,
umls-concept:C0030685,
umls-concept:C0086418,
umls-concept:C0205263,
umls-concept:C0376152,
umls-concept:C0391871,
umls-concept:C0443252,
umls-concept:C0680255,
umls-concept:C1283071,
umls-concept:C1522492,
umls-concept:C1963578
|
pubmed:issue |
11
|
pubmed:dateCreated |
1990-6-28
|
pubmed:abstractText |
IL-6 enhances the differentiation of pluripotent hematopoietic stem cells but predominantly affects the differentiation of hematopoietic cells in the granulocyte-macrophage lineage. We have previously shown that multinucleated cells (MNC) with many features of the osteoclast phenotype form in long term human marrow cultures. Addition of rhIL-6 (10 to 100 pg/ml) to these cultures significantly increased MNC formation, with greater than 80% of the MNC expressing an Ag that cross-reacts with the mAb 23c6. This antibody preferentially binds to osteoclasts. rhIL-6 did not enhance MNC formation in marrow cultures treated with 1,25 dihydroxyvitamin D3, a potent stimulator of MNC formation, but significantly increased the percentage of MNC that cross-reacted with the 23c6 mAb. Addition of antihuman IL-1 to cultures treated with rhIL-6 totally inhibited the increase in MNC formation stimulated by rhIL-6. In contrast, anti-IL-1 did not affect MNC formation stimulated by 1,25 dihydroxyvitamin D3. Further, conditioned media from marrow cultures exposed to rhIL-6 contained elevated levels of IL-1 beta (500 pg/ml compared to 23 pg/ml in control cultures 15 h after IL-6 addition). These results suggest that the capacity of rhIL-6 to stimulate formation of MNC which cross-react with 23c6 is mediated by induction of release of IL-1 beta.
|
pubmed:grant | |
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
AIM
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Antibodies, Monoclonal,
http://linkedlifedata.com/resource/pubmed/chemical/Calcitonin,
http://linkedlifedata.com/resource/pubmed/chemical/Interleukin-1,
http://linkedlifedata.com/resource/pubmed/chemical/Interleukin-6,
http://linkedlifedata.com/resource/pubmed/chemical/Recombinant Proteins
|
pubmed:status |
MEDLINE
|
pubmed:month |
Jun
|
pubmed:issn |
0022-1767
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:day |
1
|
pubmed:volume |
144
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
4226-30
|
pubmed:dateRevised |
2007-11-14
|
pubmed:meshHeading |
pubmed-meshheading:2341718-Antibodies, Monoclonal,
pubmed-meshheading:2341718-Bone Marrow Cells,
pubmed-meshheading:2341718-Calcitonin,
pubmed-meshheading:2341718-Cell Differentiation,
pubmed-meshheading:2341718-Cells, Cultured,
pubmed-meshheading:2341718-Humans,
pubmed-meshheading:2341718-Interleukin-1,
pubmed-meshheading:2341718-Interleukin-6,
pubmed-meshheading:2341718-Osteoclasts,
pubmed-meshheading:2341718-Recombinant Proteins,
pubmed-meshheading:2341718-Time Factors
|
pubmed:year |
1990
|
pubmed:articleTitle |
IL-6 stimulates osteoclast-like multinucleated cell formation in long term human marrow cultures by inducing IL-1 release.
|
pubmed:affiliation |
Research Service, Audie Murphy VA Hospital, San Antonio, TX 78284.
|
pubmed:publicationType |
Journal Article,
In Vitro,
Research Support, U.S. Gov't, P.H.S.,
Research Support, Non-U.S. Gov't
|